StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/303% below fair value
$33.79−0.71 (-2.06%)

Close on Nov 13, 2026Market cap $1.03BP/E –Yield 0.00%

Castle Biosciences gross margin

Gross margin is gross profit as a percentage of revenue.

Castle Biosciences's gross margin for the twelve months ending Sep 30, 2026 was 77.1%. For fiscal 2025 it was 79.4%, against 81.9% the year before. The highest annual figure on record is 85.9% in fiscal 2019.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202579.4%−2.5
FY2024Dec 31, 202481.9%+2.3
FY2023Dec 31, 202379.5%+2.9
FY2022Dec 31, 202276.6%−6.5
FY2021Dec 31, 202183.2%−1.4
FY2020Dec 31, 202084.5%−1.4
FY2019Dec 31, 201985.9%+9.2
FY2018Dec 31, 201876.8%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202676.8%−0.7
Q2 FY2026Jun 30, 202677.1%−2.4
Q1 FY2026Mar 31, 202675.5%−5.9
Q4 FY2025Dec 31, 202579.0%−2.3
Q3 FY2025Sep 30, 202577.5%−4.3
Q2 FY2025Jun 30, 202579.5%−3.8
Q1 FY2025Mar 31, 202581.4%+0.4
Q4 FY2024Dec 31, 202481.3%+0.0
Q3 FY2024Sep 30, 202481.8%+0.2
Q2 FY2024Jun 30, 202483.3%+5.4
Q1 FY2024Mar 31, 202481.0%+5.2
Q4 FY2023Dec 31, 202381.2%+6.0
Q3 FY2023Sep 30, 202381.6%+5.5
Q2 FY2023Jun 30, 202377.9%+0.0
Q1 FY2023Mar 31, 202375.8%−2.1
Q4 FY2022Dec 31, 202275.2%−6.5
Q3 FY2022Sep 30, 202276.1%−4.8
Q2 FY2022Jun 30, 202277.9%−5.8
Q1 FY2022Mar 31, 202277.9%−8.9
Q4 FY2021Dec 31, 202181.6%−2.9
Q3 FY2021Sep 30, 202180.8%−2.9
Q2 FY2021Jun 30, 202183.8%+0.6
Q1 FY2021Mar 31, 202186.7%+0.5
Q4 FY2020Dec 31, 202084.5%−4.0
Q3 FY2020Sep 30, 202083.7%−4.7
Q2 FY2020Jun 30, 202083.1%+1.7
Q1 FY2020Mar 31, 202086.3%+4.6
Q4 FY2019Dec 31, 201988.6%+0.5
Q3 FY2019Sep 30, 201988.4%+24.8
Q2 FY2019Jun 30, 201981.4%+14.8
Q1 FY2019Mar 31, 201981.7%+15.9
Q4 FY2018Dec 31, 201888.1%–
Q3 FY2018Sep 30, 201863.6%–
Q2 FY2018Jun 30, 201866.6%–
Q1 FY2018Mar 31, 201865.8%–

More Castle Biosciences figures

See a number that looks wrong?